Home > Press > Exclusive agreement to distribute Affinity Biosensors’ Archimedes system extends Malvern Instruments’ biopharma solutions
Malvern Instruments will distribute the Archimedes system outside USA & Canada. |
Abstract:
Materials characterization company Malvern Instruments Ltd. (Malvern, UK) has signed an exclusive distribution agreement with Affinity Biosensors LLC (Santa Barbara, CA, USA) which will extend the range of solutions that Malvern offers to the biopharmaceutical sector. The distribution agreement covers all geographies outside the USA and Canada.
Under the terms of the agreement Malvern will distribute the Archimedes Particle Metrology system, developed and manufactured by Affinity Biosensors, through its subsidiaries in Europe and Asia. Malvern will establish a co-marketing arrangement with Affinity Biosensors in North America.
Archimedes, which won the Pittcon Editors Gold Award in 2010 and an R&D100 Award in 2010, employs a unique patented technology co-invented by the Massachusetts Institute of Technology (MIT) and Affinity Biosensors. Using the technique of Resonant Mass Measurement (RMM), Archimedes detects and counts particles and determines their mass and size with high resolution and accuracy, in small sample volumes. A key area of application is the measurement of protein aggregation in biotherapeutic formulations, which provides critical information needed to speed development and improve drug safety and efficacy. Archimedes provides the technology to both count and characterize aggregates, making it invaluable to biopharmaceutical manufacturers and developers.
"We are very pleased to be involved with this exciting new technology and to be adding it to our growing range of solutions for biopharmaceutical researchers," said Duncan Roberts, Business Development Director for Malvern. "Protein aggregation is a significant challenge in the development of protein-based drugs, and an area of increasing interest and potential regulation. Archimedes will sit alongside Malvern's Zetasizer and Viscotek systems, all of which deliver complementary solutions for customers in this fast growing pharmaceutical industry sector."
Affinity Biosensors' CEO Ken Babcock commented, "Archimedes has been adopted at many leading US biopharmaceutical companies. Our partnership with Malvern will extend Archimedes' reach worldwide, and we are glad to see it alongside Malvern's leading materials characterization technology. Archimedes users are sure to benefit from Malvern's world-class support and applications expertise."
Archimedes allows precise measurement of size and mass of particles with diameters down to 50nm. Measurements are unaffected by optical or shape variations, and gentle fluidics ensure that fragile aggregates are not disrupted. The instrument can measure high viscosity samples and consumes as little as 100µl of precious protein formulation. Archimedes can accept particle concentrations up to 1x109 per ml, allowing direct study of undiluted high concentration formulations.
Archimedes can also differentiate between protein aggregates and silicone oil droplets in an injectable biopharmaceutical using buoyant mass measurement, something that no other technology can do at the submicron size scale.
Details of Malvern's rapidly expanding range of protein characterization solutions are available at www.malvern.com/protein-aggregation, with full descriptions and specifications for the new Archimedes systems at www.malvern.com/archimedes
Malvern and Malvern Instruments are registered trademarks of Malvern Instruments Ltd
####
About Malvern Instruments
Malvern Instruments is a market leader in measuring performance controlling material properties. These include particle size, particle shape, zeta potential, molecular weight, size and conformation, rheological properties and chemical identification. Malvern delivers the systems, support and expertise that ensure the analytical integrity and productivity needed to drive research, development and manufacturing.
Malvern’s measurement solutions for scientists, technologists and engineers advance continually through customer collaboration. Complementary materials characterization systems deliver inter-related measurements that reflect the complexities of particulates and disperse systems, nanomaterials and macromolecules. Combining intelligently implemented technologies with in-depth industry applications knowledge and support, Malvern provides customers with the competitive advantage they demand.
Headquartered in Malvern, UK, Malvern Instruments has subsidiary organizations in all major European markets, North America, China, Japan and Korea, a joint venture in India, a global distributor network and applications laboratories around the world. www.malvern.com
Facebook: MalvernInstruments
Blog: www.materials-talks.com
Youtube: malverninstruments
Linked-In: malvern-instruments
Twitter: malvern_news
About Affinity Biosensors
Affinity Biosensors, located in Santa Barbara, California, manufactures refined analytical instruments based on resonant mass measurement. Its Archimedes Particle Metrology System has been adopted by numerous leading biopharmaceutical companies to measure protein aggregation in the submicron size range, and at industrial and academic institutions to characterize nanoparticles. Affinity Biosensors will continue to provide sales and support to its customers throughout North America. Affinity Biosensors is also developing RMM-based instruments for rapid antibiotic susceptibility testing and ultra-high precision measurements of cell growth. www.affinitybio.com
For more information, please click here
Contacts:
Please send sales enquiries to:
Alison Vines
Malvern Instruments Ltd
Enigma Business Park, Grovewood Road
Malvern, Worcestershire WR14 1XZ UK
Tel: +44 (0) 1684 892456
Fax: +44 (0) 1684 892789
For North American sales enquiries, contact:
David Hopton
Affinity Biosensors
75D Robin Hill Rd
Santa Barbara, CA 93117
Tel: 1 760 565 6984
For press information, please contact:
Trish Appleton
Kapler Communications
Tel: +44 (0)1480 471059
Fax: +44 (0)1480 471069
Copyright © Malvern Instruments
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Tools
Turning up the signal November 8th, 2024
Quantum researchers cause controlled ‘wobble’ in the nucleus of a single atom September 13th, 2024
Faster than one pixel at a time – new imaging method for neutral atomic beam microscopes developed by Swansea researchers August 16th, 2024
Patents/IP/Tech Transfer/Licensing
Getting drugs across the blood-brain barrier using nanoparticles March 3rd, 2023
Metasurfaces control polarized light at will: New research unlocks the hidden potential of metasurfaces August 13th, 2021
Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda November 27th, 2020
Nanobiotechnology
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
The mechanism of a novel circular RNA circZFR that promotes colorectal cancer progression July 5th, 2024
Alliances/Trade associations/Partnerships/Distributorships
Chicago Quantum Exchange welcomes six new partners highlighting quantum technology solutions, from Chicago and beyond September 23rd, 2022
University of Illinois Chicago joins Brookhaven Lab's Quantum Center June 10th, 2022
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||